Complete Response To Eribulin In A Patient With Unresectable Liposarcoma: A Case Report And Implications Of New Biomarkers

Hajime Nakamura; Kohichi Takada; Makoto Emori; Naotaka Hayasaka; Shintaro Sugita

doi:10.2169/internalmedicine.9423-22

This article has now been updated. Please use the final version.

Complete Response To Eribulin In A Patient With Unresectable Liposarcoma: A Case Report And Implications Of New Biomarkers

Hajime Nakamura, Kohichi Takada, Makoto Emori, Naotaka Hayasaka, Shintaro Sugita

Author information

Keywords: eribulin, liposarcoma, phosphorylated AKT

JOURNAL OPEN ACCESS Advance online publication

Article ID: 9423-22

DOI https://doi.org/10.2169/internalmedicine.9423-22

The final version of this article is now available: Vol. 61 (2022), No. 23 pp. 3617-3621

Details

Abstract

We herein report a rare case of unresectable liposarcoma that showed a complete response to eribulin. Furthermore, a low expression of phosphorylated AKT (p-AKT) on an immunohistological evaluation was observed. This result is consistent with our previous preclinical study that demonstrated the significance of p-AKT signaling for eribulin resistance in multiple subtypes of soft tissue sarcoma (STS) cells. This case highlights the potential benefits of eribulin as well as the mechanism underlying resistance to eribulin in patients with unresectable or metastatic STS, especially liposarcoma.

Corresponding author

Register with J-STAGE for free!